Docoh
Loading...
Sign up Log in

DXCM Dexcom

DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Company profile

Ticker
DXCM
Exchange
NASDAQ
Website
www.dexcom.com/
CEO
Kevin Sayer
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Dec 31
Sector
Manufacturing > Surgical and Medical Instrument Manufacturing
Industry (SIC)
Surgical & Medical Instruments & Apparatus
Boston Scientific • Baxter International • Becton, Dickinson And • 3M • Stryker • Teleflex • Resmed • Hill-Rom • Integra Lifesciences • Nuvasive ...
SEC CIK
0001093557
Corporate docs
IRS number
330857544

DXCM stock data

(
)

News

Pro users get this 30m faster
Benzinga's Top Ratings Upgrades, Downgrades For April 15, 2021
15 Apr 21
Atlantic Equities Initiates Coverage On DexCom with Overweight Rating, Announces Price Target of $438
15 Apr 21
Atlantic Equities initiates coverage on DexCom (NASDAQ:DXCM) with a Overweight rating and announces Price Target of $438.
Mid-Morning Market Update: US Stock Futures Trend Down; Nasdaq Composite Dips 0.2%
12 Feb 21
Following the market opening Friday, the Dow declined 0.09% to 31,402.67, while the NASDAQ fell 0.21% to 13,996.18. The S&P also plunged 0.05% to 3,914.51. Leading and Lagging Sectors
Citigroup Maintains Buy on DexCom, Lowers Price Target to $480
12 Feb 21
Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $410
12 Feb 21

Press releases

Pro users get this 30m faster
Manitoba and Saskatchewan Promise to Make Life-Changing Dexcom G6 CGM System Accessible for Children and Young Adults with Type 1 Diabetes
16 Apr 21
Dexcom G6 gives people with diabetes the power to manage their condition without fingersticks* or scanning BURNABY, BC, April 16, 2021 /CNW/ - Dexcom, Inc. (NASDAQ:DXCM), a leader in real-time continuous glucose
Dexcom Schedules First Quarter 2021 Earnings Release and Conference Call for April 29, 2021 at 4:30 p.m. Eastern Time
1 Apr 21
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, April 29, 2021. Management will hold a conference call to review the
Dexcom Promotes Jereme Sylvain to Chief Financial Officer
23 Mar 21
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring, today announced the promotion of Jereme Sylvain to the role of Executive Vice President and Chief Financial Officer. In his
Dexcom Announces Upcoming Virtual Conference Presentations
17 Feb 21
Dexcom Launches Inaugural Venture Capital Fund
11 Feb 21

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Feb 21
17 Apr 21
31 Dec 21

Financial summary

Financial statements Chart DXCM financial data
Quarter (USD)
 Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Dexcom earnings reports.

Recent insider trades

DXCM insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Apr 21 Paul R Flynn Common Stock Sell Dispose S No Yes 400 758 303.2K 12,306
5 Apr 21 Sayer Kevin R Common Stock Sell Dispose S No Yes 367.4105 1,179 433.18K 111,257
5 Apr 21 Sayer Kevin R Common Stock Sell Dispose S No Yes 366.8449 3,567 1.31M 112,436
5 Apr 21 Sayer Kevin R Common Stock Sell Dispose S No Yes 365.674 1,475 539.37K 116,003
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

DXCM institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

93.0% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 709 714 -0.7%
Opened positions 106 90 +17.8%
Closed positions 111 80 +38.8%
Increased positions 283 278 +1.8%
Reduced positions 241 256 -5.9%
13F shares
 Current Prev Q Change
Total value 33.23B 38.55B -13.8%
Total shares 89.9M 90.08M -0.2%
Total puts 1.91M 1.12M +70.4%
Total calls 1.44M 1.35M +6.2%
Total put/call ratio 1.3 0.8 +60.4%
Largest owners
 Shares Value Change
Vanguard 10.23M $3.78B -1.5%
BLK Blackrock 7.01M $2.59B -3.5%
FMR 6.98M $2.58B -18.6%
Baillie Gifford & Co 5.45M $2.02B +29.0%
STT State Street 3.86M $1.43B -1.7%
MS Morgan Stanley 3.11M $1.15B -24.5%
JPM JPMorgan Chase & Co. 3.06M $1.13B -0.5%
Sands Capital Management 2.29M $847M -1.7%
Lone Pine Capital 2.27M $838.45M +389.7%
TROW T. Rowe Price 2.14M $790.94M -31.1%
Largest transactions
 Shares Bought/sold Change
Lone Pine Capital 2.27M +1.8M +389.7%
FMR 6.98M -1.59M -18.6%
Baillie Gifford & Co 5.45M +1.23M +29.0%
MS Morgan Stanley 3.11M -1.01M -24.5%
TROW T. Rowe Price 2.14M -963.52K -31.1%
Norges Bank 766.65K +766.65K NEW
GS Goldman Sachs 340.81K -754.16K -68.9%
Jennison Associates 1.99M -747.64K -27.3%
GQG Partners 0 -673.84K EXIT
Voya Investment Management 621.45K +575.81K +1261.8%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Abbott Laboratories • Insulet • Integrity Applications • DarioHealth • Senseonics
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: AB, abandon, absent, acid, add, advocate, African, ago, AKS, Altera, arbitrary, argued, Ascorbic, athlete, backend, Big, breadth, cap, career, CFR, character, chargeback, cheaper, child, citizen, citizenship, clause, COBRA, Commissioner, compliant, conserve, constitutionality, CPRA, Creation, crude, culture, decade, deeply, DEI, detrimental, dignity, dissemination, distancing, doctor, DOJ, donation, Doubleday, downturn, duration, duty, elongation, emotional, empower, entertainment, ERG, ESG, exceeded, ExhibitNumber, expedite, explicitly, facially, Faster, formula, forty, forum, foster, frontline, fullest, gender, globe, Governor, great, healthy, hub, Hydroxyurea, illustrative, impediment, inapplicable, incapacitated, inflation, Inspire, interoperability, interval, Jeffrey, journey, lab, lag, landscape, LatinX, left, legislature, legitimate, Listen, listening, Lithuania, living, macroeconomic, Malaysia, Malaysian, McKesson, mealtime, MIDA, mindset, Moy, narrowly, necessitated, Newsom, night, NOL, nonessential, nonperformance, Occupational, ofFirst, onsite, opportunity, optimistic, organizational, Orthotic, outbreak, overview, pandemic, parent, PBM, Penang, perfusion, peripheral, persisting, phishing, picture, pipeline, PPE, Presidential, PRIDE, prioritization, proactive, promulgated, pronounced, proper, ProvidedHerewith, put, quarantine, recession, reinforce, resilience, respiratory, restore, retroactive, retroactively, Richard, sanitation, science, se, shareholder, shelf, Shield, situation, sizeable, speaker, spotlight, spread, strive, stronger, Subtopic, Supreme, tailored, talent, TCJA, telework, tenure, threat, town, true, tuition, unemployment, unforeseen, untruthful, urgent, valuable, verification, vertically, viral, virtual, virtually, visibility, vision, waived, warmup, Warrior, wellbeing, wholesaler, women, workplace, Ypsomed
Removed: adjudication, adjunctive, admission, aggressively, amend, ascertain, attributed, augmented, avoidable, blind, bundled, cal, calibrated, carryforward, cellular, complicate, conflict, constituting, consuming, contributor, DIaMonD, digit, disbursed, dispensing, distributed, diversify, edition, exercisable, explained, Finally, flash, Foundation, FreeStyle, funded, hemoglobin, importation, ineligible, informal, injection, inter, intermittent, IRS, ITC, judge, Juvenile, lawfully, lessee, MARD, move, multicenter, necessity, neglect, notion, OneTouch, onset, Oregon, pediatric, phase, pilot, Ping, procedural, progression, project, pursued, radiofrequency, Radiological, regimen, reimburse, requesting, reverse, satisfying, served, session, statistically, substantive, sum, Treaty, Unaudited, unintended, UnitedHealthcare, validating, version, Vibe, viewing, Vital
From filing 10-K 2020 FY

Financial reports

View all
10-K
2020 FY
Annual report
11 Feb 21
10-Q
2020 Q3
Quarterly report
27 Oct 20
10-Q
2020 Q2
Quarterly report
28 Jul 20
10-Q
2020 Q1
Quarterly report
28 Apr 20
10-K
2019 FY
Annual report
13 Feb 20
10-Q
2019 Q3
Quarterly report
6 Nov 19
10-Q
2019 Q2
Quarterly report
31 Jul 19
10-Q
2019 Q1
Quarterly report
1 May 19
10-K
2018 FY
Annual report
21 Feb 19
10-Q
2018 Q3
Quarterly report
6 Nov 18

Current reports

View all
8-K
Departure of Directors or Certain Officers
23 Mar 21
8-K
Departure of Directors or Certain Officers
17 Mar 21
8-K
Dexcom Reports Fourth Quarter and Fiscal Year 2020 Financial Results
11 Feb 21
8-K
Results of Operations and Financial Condition
11 Jan 21
8-K
Departure of Directors or Certain Officers
10 Dec 20
8-K
Results of Operations and Financial Condition
27 Oct 20
8-K
Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue
26 Oct 20
8-K
Departure of Directors or Certain Officers
13 Oct 20
8-K
Amendments to Articles of Incorporation or Bylaws
9 Sep 20
8-K
Departure of Directors or Certain Officers
12 Aug 20

Registration and prospectus

View all
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Feb 21
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Feb 21
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Feb 21
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Feb 21
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Feb 21
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Feb 21
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Feb 21
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Feb 21
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Feb 21
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Feb 21

Proxies

View all
DEFA14A
Additional proxy soliciting materials
9 Apr 21
DEF 14A
Definitive proxy
9 Apr 21
PRE 14A
Preliminary proxy
26 Mar 21
DEFA14A
Additional proxy soliciting materials
8 May 20
DEFA14A
Additional proxy soliciting materials
10 Apr 20
DEF 14A
Definitive proxy
10 Apr 20
DEFA14A
Additional proxy soliciting materials
19 Apr 19
DEF 14A
Definitive proxy
19 Apr 19
DEF 14A
Definitive proxy
19 Apr 18
DEFA14A
Additional proxy soliciting materials
19 Apr 18

Other

View all
SD
Conflict minerals disclosure
1 Jun 20
SD
Conflict minerals disclosure
30 May 19
CT ORDER
Confidential treatment order
5 Mar 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
30 May 17
CT ORDER
Confidential treatment order
30 Mar 17
CT ORDER
Confidential treatment order
18 Sep 16
CT ORDER
Confidential treatment order
26 Jun 16
SD
Conflict minerals disclosure
30 May 16
CT ORDER
Confidential treatment order
14 Jan 16

Ownership

View all
4
DEXCOM / Paul R Flynn ownership change
16 Apr 21
4
DEXCOM / KEVIN R SAYER ownership change
7 Apr 21
3
DEXCOM / Chad Patterson ownership change
1 Apr 21
3
DEXCOM / Sumi Shrishrimal ownership change
1 Apr 21
3
DEXCOM / Paul R Flynn ownership change
1 Apr 21
4
DEXCOM / Patrick Michael Murphy ownership change
30 Mar 21
4
DEXCOM / Steven Robert Pacelli ownership change
24 Mar 21
4
DEXCOM / RICHARD DOUBLEDAY ownership change
24 Mar 21
4
DEXCOM / Jereme M Sylvain ownership change
12 Mar 21
4
DEXCOM / Shelly Ramasamy Selvaraj ownership change
12 Mar 21

Patents

View all
GRANT
Utility
Diabetes management partner interface for wireless communication of analyte data
13 Apr 21
Systems, devices, and methods are disclosed for wireless communication of analyte data.
APP
Utility
Transcutaneous Analyte Sensor
8 Apr 21
The present invention relates generally to systems and methods for measuring an analyte in a host.
GRANT
Utility
Integrated medicament delivery device for use with continuous analyte sensor
6 Apr 21
An integrated system for the monitoring and treating diabetes is provided, including an integrated receiver/hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor.
GRANT
Design
Display screen or portion thereof with graphical user interface
30 Mar 21
Inventors: Michael Robert Mensinger, Eric Cohen, Phil Mayou, Eli Reihman, Katherine Yerre Koehler, Rian Draeger, Angela Marie Traven
GRANT
Design
Medical device inserter
30 Mar 21
Inventors: Eric Gobrecht, Randall Scott Koplin, Kyle Neuser, Ryan Schoonmaker

Transcripts

View all
2020 Q4
Earnings call transcript
12 Feb 21
2020 Q3
Earnings call transcript
27 Oct 20
2020 Q2
Earnings call transcript
28 Jul 20
2020 Q1
Earnings call transcript
28 Apr 20
2019 Q4
Earnings call transcript
13 Feb 20
2019 Q3
Earnings call transcript
6 Nov 19
2019 Q2
Earnings call transcript
1 Aug 19
2019 Q1
Earnings call transcript
2 May 19
2018 Q4
Earnings call transcript
22 Feb 19
2018 Q3
Earnings call transcript
7 Nov 18

Reddit threads

View all